Microsoft vs Summit Therapeutics Inc — how do they compare? Microsoft trades at $395.99 (market cap $2.99T), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Microsoft is far larger — about 285.3× Summit Therapeutics Inc's market cap, and Microsoft pays a 0.9% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MSFT | SMMT | |
|---|---|---|
Market Cap | $2.99T | $10.48B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $29.32 |
52-Week Low | $352.83 | $13.05 |
Enterprise Value | $2.97T | $9.90B |
Dividend Yield | 0.9% | — |
Signals from Pluang's Aura AI — not financial advice
Microsoft trades at $397.75, up 1.0% with strong technical momentum as price approaches pivot point resistance at $398. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.27 versus $4.06, continuing a trend of earnings outperformance. Revenue growth accelerated to $281.72B in 2025 with net income margins expanding to 36.14%. Recent news highlights Microsoft's AI leadership through Azure and Copilot initiatives, though concerns about capital expenditures persist.
Microsoft presents a compelling investment case with 80% analyst buy ratings and a $546.70 consensus price target representing 37% upside. The company's AI positioning and cloud dominance support long-term growth, but risks include competitive pressures, high valuation multiples (P/E 23.96), and market volatility. Strong cash flow generation ($136.16B operating cash flow) and consistent dividend payments provide shareholder stability amid growth investments.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →